Detail akcie Vyome Hldgs Rg online

Business Summary: Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Vyome Holdings Inc revenues decreased 61% to $2.4M. Net loss increased 79% to $9.6M. Revenues reflect United States segment decrease of 62% to $2M, Europe segment decrease of 68% to $179K. Higher net loss reflects Gain on extinguishment of debt decrease of 94% to $24K (income), Other expense decrease of 39% to $119K (income).